Immutep Opens Randomized Phase II of AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer

 

• No safety or tolerability issues in open-label, safety lead-in phase evaluating the higher 90mg dose of efti in combination with weekly paclitaxel in the first 6 patients

• Good safety profile allows for lead-in phase to be closed early and the randomized Phase II portion of study will now proceed

https://www.biospace.com/article/releases/immutep-announces-completion-of-the-safety-lead-in-and-opening-of-the-randomized-phase-ii-of-the-aipac-003-phase-ii-iii-trial-in-metastatic-breast-cancer/